KIR3DL2 Activators are a specialized class of chemical compounds designed to specifically target and enhance the activity of the Killer cell Immunoglobulin-like Receptor 3DL2 (KIR3DL2). KIR3DL2 is a transmembrane glycoprotein expressed on the surface of natural killer (NK) cells and a subset of T cells, which are key players in the immune system's ability to recognize and respond to cellular abnormalities. The primary function of KIR3DL2 is to regulate the cytotoxic activity of NK cells through its interaction with specific ligands, including certain human leukocyte antigen (HLA) class I molecules. By engaging with these ligands, KIR3DL2 transmits inhibitory signals that modulate the immune response, maintaining a balance between activation and inhibition to prevent unwanted tissue damage. Activators in this chemical class would work by modulating the signaling pathways associated with KIR3DL2, potentially by increasing its expression, enhancing ligand binding, or by stabilizing the receptor on the cell surface. The aim of these compounds would be to fine-tune the signaling through KIR3DL2, ensuring precise control over NK cell activity.
The process of identifying and characterizing KIR3DL2 Activators involves intricate and highly technical research methodologies. Initial discovery is likely to rely on high-throughput screening of chemical libraries to identify compounds that can selectively interact with KIR3DL2. Such compounds would then undergo rigorous testing to determine the exact nature of their interaction with the receptor. This might involve binding assays to evaluate their affinity for KIR3DL2 and their impact on the receptor's conformation. Further studies could include the use of molecular biology techniques to assess changes in gene expression levels of KIR3DL2 in response to these activators. Moreover, advanced imaging techniques like flow cytometry or confocal microscopy could be employed to visualize the receptor's distribution and density on the cell membrane upon interaction with these compounds. Through these approaches, scientists gain valuable insights into the molecular dynamics governing the activity of KIR3DL2 and the potential for precise modulation by these activators. This research contributes to a broader understanding of immune cell regulation and the complex interplay of signals that govern the immune system's surveillance mechanisms.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
May modulate immune cell differentiation and lead to changes in the expression of receptors like KIR3DL2. | ||||||
1α,25-Dihydroxyvitamin D3 | 32222-06-3 | sc-202877B sc-202877A sc-202877C sc-202877D sc-202877 | 50 µg 1 mg 5 mg 10 mg 100 µg | $220.00 $645.00 $1000.00 $1500.00 $440.00 | 32 | |
This active form of vitamin D3 can modulate immune responses, possibly affecting NK cell receptor expression. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A DNA methyltransferase inhibitor that could alter gene expression profiles, possibly including KIR3DL2. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
Similar to azacytidine, this compound may change DNA methylation status and affect KIR expression. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
As an HDAC inhibitor, it may impact chromatin structure and gene expression, potentially influencing KIR3DL2 levels. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Another HDAC inhibitor that might alter the expression of genes in NK cells, including those for KIR3DL2. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
An immunomodulatory drug that could affect the expression of various immune receptors on NK cells. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
It has immunomodulatory effects and may influence the phenotype of NK cells, including KIR expression. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
This proteasome inhibitor can affect the turnover of many proteins and potentially alter the expression of immune receptors. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
An immunosuppressant that can affect the activation and differentiation of T cells, potentially indirectly affecting NK cells. | ||||||